Search results
Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study
Zacks via Yahoo News· 9 months agoJasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic...
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review
Zacks via Yahoo News· 1 year agoSanofi SNY announced that the supplemental biologics license application (sBLA) for the label...
Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk
Zacks via Yahoo News· 11 months agoThis week, Eli Lilly LLY, Bayer BAYRY and Novo Nordisk NVO announced second-quarter earnings. Novo...
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Zacks via Yahoo News· 2 months agoSanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo News· 2 months agoThe first-quarter 2024 earnings season picked up pace this week, with Merck MRK, Sanofi SNY,...
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Zacks via Yahoo News· 2 months agoSanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III...
Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints
Zacks via Yahoo News· 2 years agoRoche (RHHBY) performance in the first half was decent on demand for its diagnostics base business...
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
Zacks via Yahoo News· 1 year agoA mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a...
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Zacks via Yahoo News· 1 year agoRoche Holding AG’s RHHBY performance in 2022 was pretty average, as the demand for COVID-19 products...
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
Zacks via Yahoo News· 7 months agoSwiss pharma giant Novartis NVS raised its sales and operating income goals for the mid-term, post...